# EDGAR Filing Document

**Accession Number:** 0001789192
**File Stem:** 0001493152-25-012130
**Filing Date:** 2025-8
**Character Count:** 23124
**Document Hash:** 9ee52dc76ebe6a796a6b573b7f9c7520
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-012130.hdr.sgml**: 20250818

**ACCESSION NUMBER**: 0001493152-25-012130

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250817

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250818

**DATE AS OF CHANGE**: 20250818

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** N2OFF, Inc.
- **CENTRAL INDEX KEY:** 0001789192
- **STANDARD INDUSTRIAL CLASSIFICATION:** AGRICULTURE CHEMICALS [2870]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 264684680
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40403
- **FILM NUMBER:** 251227942

**BUSINESS ADDRESS:**
- **STREET 1:** 156 FIFTH AVENUE 10TH FLOOR
- **STREET 2:** CO EARTHBOUND LLC
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010-7751
- **BUSINESS PHONE:** 972544561349

**MAIL ADDRESS:**
- **STREET 1:** 156 FIFTH AVENUE 10TH FLOOR
- **STREET 2:** CO EARTHBOUND LLC
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010-7751

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Save Foods, Inc.
- **DATE OF NAME CHANGE:** 20230410

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Save Foods Inc.
- **DATE OF NAME CHANGE:** 20190924

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** August 17, 2025

**<u>N2OFF, Inc.</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | **001-40403** | **26-4684680** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (IRS Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **HaPardes 134 (Meshek Sander)**<br> **Neve Yarak, Israel** | **4994500** |
| (Address of principal executive offices) | (Zip Code) |

---

**<u>(347) 468- 9583</u>**

(Registrant's telephone number, including area code)

**<u>N/A</u>**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of exchange on which registered** |
| Common Stock, par value $0.0001 per share | NITO | The Nasdaq Capital Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01 Entry into a Material Agreement**

*Fourth Loan Agreement*

On August 17, 2025, N2OFF, Inc. (the "Company") entered into a fourth loan agreement (the "Fourth Loan Agreement") with MitoCareX Bio Ltd., a private company incorporated under the laws of the State of Israel ("MitoCareX") and L.I.A. Pure Capital Ltd., an Israeli company ("Pure Capital") pursuant to which the Company agreed to loan $372,000 (the "Principal") to MitoCareX with interest accruing at an annual rate pursuant to Section 3(j) of the Income Tax Ordinance, published by the Israel Tax Authority for loans in US dollars, which is currently the USD exchange rate fluctuation until the maturity date plus 3%, as may be adjusted from time to time (the "Loan"). The term of the Loan is six months with repayment of the Principal and accrued interest due at maturity. In the event of a transaction whereby MitoCareX becomes a subsidiary of the Company, any amount outstanding under the Loan will be deducted from any future amount allocated by the Company to MitoCareX during the first year following the foregoing transaction. Pure Capital has agreed to guarantee the repayment of the Loan.

As previously disclosed in its Current Report on Form 8-K filed on February 26, 2025, the Company entered into a securities purchase and exchange agreement on February 25, 2025 (the "Agreement") with MitoCareX, SciSparc Ltd., a public company incorporated under the laws of the State of Israel ("SciSparc"), Dr. Alon Silberman ("Alon"), and Prof. Ciro Leonardo Pierri ("Ciro", together with SciSparc and Alon, the "Sellers"). Pursuant to the Agreement, the Company will acquire from each of the Sellers their respective ordinary shares, nominal (par) value NIS 0.01 each, of MitoCareX, thereby resulting in MitoCareX becoming a wholly-owned subsidiary of the Company. The closing of the transactions contemplated thereunder is subject to the terms and conditions of the Agreement, including obtaining approval from the Company's stockholders. The purpose of the Fourth Loan Agreement is to assist MitoCareX with financing its ongoing costs and obligations until the closing of the Agreement has occurred.

The foregoing description of the Fourth Loan Agreement is not complete and is qualified in its entirety by reference to the full text of the Fourth Loan Agreement, a copy of which is filed hereto as Exhibit 10.1, and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<u>Exhibit No.</u> <u>Description</u> <br> 10.1 [Loan Agreement, dated August 17, 2025, among the Company, MitoCareX Bio Ltd. and L.I.A. Pure Capital Ltd.](ex10-1.htm) <br> 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | N2OFF, Inc. | N2OFF, Inc. |
| Date: August 18, 2025 | By: | */s/ David Palach* |
|  | Name: | David Palach |
|  | Title: | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**<u>LOAN AGREEMENT</u>**

This Agreement (the "**Agreement**") is effective as of August 17, 2025 by and between MitoCareX Bio Ltd., a private company incorporated under the laws of the State of Israel, whose principal address is at 40 Gordon Street, Givatayim, Israel (the "**Company**") and the lender, who will provide the Company a loan amount as set forth in <u>Schedule A</u> (the "**Lender**") and such entity listed on <u>Schedule B</u> hereto (the "**Guarantor**"). The Company, the Lender and the Guarantor are referred to collectively as the "**Parties**" and individually as a "**Party**".

**WHEREAS,** the Company desires funding to cover its immediate obligations and working capital requirements; and

**WHEREAS,** the Lender has agreed to provide the amount as set forth in <u>Schedule A</u> to the Company in the form of a loan (the "**Loan**"), subject to the terms and conditions of this Agreement.

**NOW, THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS:**

**1.**  **<u>Preamble</u>** 

The preamble to this Agreement shall constitute an integral part hereof.

**2.**  **<u>Terms of the Loan</u>** 

&nbsp;&nbsp;&nbsp;&nbsp;2.1 The
 Lender hereby commits to provide the Company a Loan in the aggregate amount of USD 372,000
 (Three Hundred and Seventy-Two Thousand United States Dollars) as set forth in <u>Schedule A</u> (the "**Principal Amount** "), for a period of six (6) months following
 the date the Principal Amount is provided to the Company (the "**Maturity Date** ").
 The Principal Amount shall be provided to the Company as follows: (i) USD 200,000 (Two Hundred
 Thousand United States Dollars) shall be provided immediately following the date of this
 Agreement; (ii) USD 86,000 (Eighty-Six Thousand
 United States Dollars) shall be provided on September 15, 2025; and (iii) USD 86,000 (Eighty-Six
 Thousand United States Dollars) shall be provided on October 15, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;2.2 The
 Principal Amount shall bear interest at an annual rate in accordance with the rate published
 by the Israel Tax Authority pursuant to section 3(j) of the Income Tax Ordinance, for loans
 in USD, which is currently the USD exchange rate fluctuation until the Maturity Date plus
 3%, as may be adjusted from time to time (the "**Interest** ", and together
 with the Principal Amount, the "**Loan Amount** ").

&nbsp;&nbsp;&nbsp;&nbsp;2.3 The
 Interest accrued on the Principal Amount shall be repaid to the Lender on the Maturity Date.

&nbsp;&nbsp;&nbsp;&nbsp;2.4 In
 the event of the closing of a transaction in which the Company becomes a subsidiary of the
 Lender (the "**Transaction** "), the Loan Amount shall be deducted from the
 amount to be allocated by the Lender to the Company during the first year following the Transaction.

&nbsp;&nbsp;&nbsp;&nbsp;2.5 The
 Company shall be entitled to voluntary prepay the Loan Amount (for the avoidance of doubt,
 including the Interest) in whole or in part, prior to Maturity Date only with the prior written
 approval of the Lender.

---

| | |
|:---|:---|
| 3 | **<u>Guaranty</u>** |

---

&nbsp;&nbsp;&nbsp;&nbsp;3.1 Subject
 to the limitation set forth below, the Guarantor hereby absolutely, irrevocably and unconditionally
 guarantees to Lender the prompt payment of the Loan Amount in full when due in accordance
 with the terms of this Agreement. The guaranty in this ‎Section 3 (this "**Guaranty** ")
 is a guaranty of payment and not of collection and is a continuing guaranty and shall apply
 to all of the obligations whenever arising.

&nbsp;&nbsp;&nbsp;&nbsp;3.2 The
 obligations of the Guarantor hereunder are absolute and unconditional, irrespective of the
 value, genuineness, validity, regularity or enforceability of this Agreement or any other
 agreement or instrument referred to herein, to the fullest extent permitted by applicable
 law, irrespective of any other circumstance whatsoever which might otherwise constitute a
 legal or equitable discharge or defense of a surety or guarantor, each of which are hereby
 waived.

&nbsp;&nbsp;&nbsp;&nbsp;3.3 The
 Guarantor expressly waives to the fullest extent permitted by applicable law: (a) notice
 of acceptance of this Guaranty by Lender and of all extensions of credit to the Guarantor
 by Lender; (b) presentment and demand for payment or performance of any of the Obligations;
 (c) notice of Lender obtaining, amending, substituting for, releasing, waiving or modifying
 of the Principal Amount, (d) all other notices to which the Guarantor might otherwise be
 entitled.

---

| | |
|:---|:---|
| 4 | **<u>Representations and Undertakings of the Company</u>** |

---

The Company hereby represents and warrants to the Lenders as follows:

&nbsp;&nbsp;&nbsp;&nbsp;4.1 The
 Company is an entity duly organized, validly existing and in good standing under the laws
 of the State of Israel.

&nbsp;&nbsp;&nbsp;&nbsp;4.2 The
 Company has all requisite power and authority to execute and deliver this Agreement and to
 consummate the transactions and perform its obligations contemplated hereby.

&nbsp;&nbsp;&nbsp;&nbsp;4.3 This
 Agreement has been duly and validly authorized, executed and delivered by the Company and
 it constitutes a binding obligation of the Company, enforceable against it in accordance
 with the applicable laws of the State of Israel and (i) as limited by applicable bankruptcy,
 insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application
 relating to or affecting the enforcement of creditors' rights generally, and (ii) as
 limited by laws relating to the availability of specific performance, injunctive relief,
 or other equitable remedies.

&nbsp;&nbsp;&nbsp;&nbsp;4.4 The
 execution of this Agreement and the performance of any of the transactions contemplated by
 it do not and shall not contravene or constitute a default under, or cause to be exceeded,
 any limitation on the Company or the powers of its directors imposed by or contained in.

&nbsp;&nbsp;&nbsp;&nbsp;4.5 The
 entry into this Agreement by the Company does not conflict with: (i) any applicable law;
 (ii) the articles of association of the Company or any of its other constitutional documents;
 or (iii) any agreement which it is a party or under which it is bound.

&nbsp;&nbsp;&nbsp;&nbsp;4.6 No
 consent, approval, order or authorization of any third party, or registration, qualification,
 designation, declaration or filing with governmental authority is required on the part of
 the Company in connection with the consummation of the transactions contemplated by this
 Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;4.7 There
 is no action, suit, claim, proceeding, inquiry or investigation before or by any court, public
 board, government agency, self-regulatory organization or body pending against or, to the
 knowledge of the Company, threatened against the Company. The Company is not subject to any
 order, writ, judgment, injunction, decree or award of any court or any governmental authority.

&nbsp;&nbsp;&nbsp;&nbsp;4.8 The
 Company has not been advised, nor does the Company have reason to believe, that it is not
 conducting its business in all material respects, in compliance with all applicable laws,
 rules and regulations of the jurisdictions in which it is conducting its business.

&nbsp;&nbsp;&nbsp;&nbsp;4.9 No
 insolvency proceedings have been commenced by, or have been threatened against the Company,
 and there has been no other event that, to the knowledge of the Company, could be deemed
 an insolvency event or which could be classified as insolvent pursuant to the Insolvency
 and Financial Rehabilitation Law 5778-2018 or any other applicable law

---

| | |
|:---|:---|
| 5 | **<u>Representations and Warranties of the Guarantor</u>** |

---

The Guarantor hereby represents and warrants to the Lenders as follows:

&nbsp;&nbsp;&nbsp;&nbsp;5.1 The
 Guarantor is an entity duly organized, validly existing and in good standing under the laws
 of the State of Israel.

&nbsp;&nbsp;&nbsp;&nbsp;5.2 The
 Guarantor has all requisite power and authority to execute and deliver this Agreement and
 to consummate the transactions and perform its obligations contemplated hereby.

&nbsp;&nbsp;&nbsp;&nbsp;5.3 The
 execution, delivery, and performance of this Agreement is within the Guarantor's respective
 powers (as applicable), have been duly authorized, and are not in conflict with nor constitute
 a breach of any provision contained in Guarantor's organizational documents, nor will
 they constitute an event of default under any material agreement by which Guarantor is bound.
 The Guarantor is not in default under any agreement by which it is bound, except to the extent
 such default would not reasonably be expected to cause a material adverse effect on the business
 or assets or properties of the Guarantor.

&nbsp;&nbsp;&nbsp;&nbsp;5.4 The
 fair salable value (taken on a going concern basis) of the Guarantor's assets (including
 goodwill and uncalled capital commitments minus disposition costs) exceeds the fair value
 of its liabilities; the Guarantor is not left with unreasonably small capital after the transactions
 in this Agreement; and the Guarantor is able to pay its debts (including trade debts) as
 they mature.

&nbsp;&nbsp;&nbsp;&nbsp;5.5 The
 Guarantor has good title to its assets, free and clear of any and all liens except (1) liens
 existing prior to the commencement date of this Agreement and (2) liens for taxes, fees,
 assessments or other government charges or levies, either (i) not due and payable or (ii)
 being contested in good faith and for which the Guarantor maintains adequate reserves on
 its books in respect to the Loan Amount.

&nbsp;&nbsp;&nbsp;&nbsp;5.6 No
 consent, approval, order or authorization of any third party, or registration, qualification,
 designation, declaration or filing with governmental authority is required on the part of
 the Guarantor in connection with the consummation of the transactions contemplated by this
 Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;5.7 There
 is no action, suit, claim, proceeding, inquiry or investigation before or by any court, public
 board, government agency, self-regulatory organization or body pending against or, to the
 knowledge of the Guarantor, threatened against the Guarantor. The Guarantor is not subject
 to any order, writ, judgment, injunction, decree or award of any court or any governmental
 authority.

&nbsp;&nbsp;&nbsp;&nbsp;5.8 No
 insolvency proceedings have been commenced by, or have been threatened against the Guarantor,
 and there has been no other event that could be deemed an insolvency event or which could
 be classified as insolvent pursuant to the Insolvency and Financial Rehabilitation Law 5778-2018
 or any other applicable law.

---

| | |
|:---|:---|
| 6 | **<u>Taxes</u>** |

---

Each Party shall bear its own tax liability (including any withholding tax, if any), deriving from all rights and benefits granted under this Agreement, including without limitation all present or future taxes, levies, deductions, penalties, fines, or similar liability under any applicable law.

---

| | |
|:---|:---|
| 7 | **<u>Expenses</u>** |

---

Each Party will bear its own legal fees and any other expenses with respect to this Agreement.

---

| | |
|:---|:---|
| 8 | **<u>Confidentiality</u>** |

---

Each Party hereto agrees to: (a) subject to the reporting requirements of Lender and the obligations relating thereto, keep the existence of this Agreement and all matters contained herein strictly confidential and not to disclose them, except to their board members, officers and shareholders, and their legal, accounting and other advisers; (b) to consult with each other and agree on desirability, timing and substance of any public announcement or disclosure to the public relating to the Agreement, subject to any applicable law or requirement by any authority.

---

| | |
|:---|:---|
| 9 | **<u>Entire Agreement; Amendment</u>** |

---

The Parties acknowledge and agree that this Agreement is the entire complete and exclusive statement of their agreement relating to the subject matter hereof and supersedes all other proposals (whether oral or written), understandings, representations, conditions, and other communications between the Parties relating hereto. This Agreement may be amended only by a subsequent writing that specifically refers to this Agreement and is signed by all Parties, and no other act, document, usage, or custom shall be deemed to amend this Agreement.

---

| | |
|:---|:---|
| 10 | **<u>Governing Law; Dispute Resolution</u>** |

---

This Agreement shall be governed by and construed exclusively in accordance with the laws of the State of Israel. Any and all disputes arising out of or in connection with the execution, interpretation, performance, or non-performance of this Agreement, that are not resolved amicably and in good faith by the Parties, shall be resolved by the competent courts in Tel-Aviv, Israel.

---

| | |
|:---|:---|
| 11 | **<u>Assignment</u>** |

---

Neither Party may assign any of its rights or obligations under this Agreement without the express prior written consent of the other Parties.

---

| | |
|:---|:---|
| 12 | **<u>Waivers</u>** |

---

A failure or delay in exercising a right or remedy provided by this Agreement or by law does not constitute a waiver of the right or remedy or a waiver of other rights or remedies. No single or partial exercise of a right or remedy provided by this Agreement or by law prevents further exercise of the right or remedy or exercise of another right or remedy.

---

| | |
|:---|:---|
| 13 | **<u>Further Assurance</u>** |

---

Each Party shall do and execute, or arrange for the doing and executing of, each necessary act, document and thing reasonably within its power to implement this Agreement.

---

| | |
|:---|:---|
| 14 | **<u>Notices</u>** |

---

All notices, certificates, acknowledgements and other responses hereunder shall be in writing and shall be deemed properly delivered after one (1) business day if delivered by e-mail as follows: if to the Company alon.silberman@mitocarexbio.com, if to the Lender david@n2off.com and if to the Guarantor kfir@shremzilberman.com, or seven (7) business days after being duly mailed by registered mail to the other Party.

---

| | |
|:---|:---|
| 15 | **<u>Severability</u>** |

---

If any term or provision of this Agreement is found to be illegal or unenforceable, the validity of the remainder of the Agreement will remain in full force and effect.

---

| | |
|:---|:---|
| 16 | **<u>Counterparts</u>** |

---

This Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument. Facsimile signatures shall be binding as original signature.

[*remainder of page intentionally left blank- signature page follows*]

**IN WITNESS WHEREOF**, the Parties have caused this Agreement to be executed by their duly authorized signatories identified below as of this 17 day of August 2025.

---

| | |
|:---|:---|
| **<u>LENDER</u>**: | **<u>LENDER</u>**: |
| **N2OFF, INC.** | **N2OFF, INC.** |
| By: | */s/ David Palach* |
| Name: | David Palach |
| Title: | CEO |
| **<u>COMPANY</u>**: | **<u>COMPANY</u>**: |
| **MITOCAREX BIO LTD.** | **MITOCAREX BIO LTD.** |
| By: | */s/ Alon Silberman* |
| Name: | Alon Silberman |
| Title: | Director |
| **<u>GUARANTOR</u>**: | **<u>GUARANTOR</u>**: |
| **L.I.A. PURE CAPITAL LTD.** | **L.I.A. PURE CAPITAL LTD.** |
| By: | */s/ Kfir Silberman* |
| Name: | Kfir Silberman |
| Title: | CEO |

---

[*signature page to N2Off – MitocareX Loan Fourth Loan Agreement August 17, 2025*

**<u>Schedule A</u>**

**<u>List of Lenders</u>**

---

| | |
|:---|:---|
| **Lender Name** | **Amount of the Loan (in USD)** |
| N2OFF, Inc company# 26-4684680 | 372000 |
| **TOTAL** | **372,000** |

---

**<u>Schedule B</u>**

**<u>List of Guarantors</u>**

---

| | |
|:---|:---|
| **Guarantor Name** | **Amount Guaranteed (in USD)** |
| L.I.A. Pure Capital Ltd. | 372000 |
| **TOTAL** | **372,000** |

---